Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Bio-Thera Reports Positive Results from Phase III Trial of Avastin Biosimilar

publication date: Feb 3, 2020

Bio-Thera Solutions of Guangzhou reported positive top-line results from a Phase III clinical trial of its Avastin biosimilar. The trial compared the overall response rate (ORR) of BAT1706 to Avastin as a first-line treatment for non-squamous non-small cell lung cancer. The company plans to file for approval of the Avastin biosimilar this year in China, the US and the EU. One year ago, Bio-Thera out-licensed developing country rights for BAT1706 to India's Cipla Pharma. Bio-Thera is already marketing a Humira® biosimilar for auto-immune conditions in China. More details....

Stock Symbol: (BSE: 500087)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.